Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results